期刊文献+

西格列汀对db/db糖尿病小鼠坐骨神经传导速度的影响 被引量:6

Effects of Sitagliptin on Motor Nerve Conduction Velocity of Sciatic Nerve in db/db Mice
下载PDF
导出
摘要 目的探讨西格列汀对db/db糖尿病小鼠坐骨神经传导速度的影响。方法将60只12周龄的db/db小鼠随机分为3组:西格列汀组、二甲双胍组、db/db组,各20只,分别给予8周西格列汀、二甲双胍、安慰剂灌胃治疗。另选取20只同周龄、同窝出生的db/m非糖尿病小鼠(对照组)。治疗8周后行腹腔葡萄糖耐量试验(IPGTT),治疗前后分别测定4组小鼠的坐骨神经传导速度。结果与db/db组比较,西格列汀和二甲双胍组治疗8周后空腹血糖显著下降(P<0.05),而西格列汀组与二甲双胍组比较差异无统计学意义(P>0.05)。糖负荷120 min后西格列汀和二甲双胍组小鼠葡萄糖曲线下面积和胰岛素曲线下面积均显著低于db/db组(P<0.05),但两组间差异无统计学意义(P>0.05)。西格列汀组小鼠治疗后坐骨神经传导速度显著高于db/db组和二甲双胍组(P<0.05),而二甲双胍组与db/db组比较差异无统计学意义(P>0.05)。结论西格列汀降低血糖的同时能提高坐骨神经传导速度,其作用独立于降糖作用。 Objective To investigate the effects of sitagliptin on motor nerve conduction velocity(MNCV) of sciatic nerve in db/db mice.Methods Sixty db/db mice of 12-week-old were randomized into three groups(20 each) and were administered with sitagliptin 10 mg·kg-1·d-1,metformin 150 mg·kg-1·d-1,or placebo.Another 20 age-matched nondiabetic littermates db/m mice were treated with placebo and defined as the control group.Intraperitoneal glucose tolerance test(IPGTT) was carried out after 8 weeks of treatment.Motor nerve conduction velocity of sciatic nerve was determined both before and after the treatment.Results After 8 weeks of treatment,levels of fasting plasma glucose significantly decreased in the sitagliptin and the metformin group compared with the db/db control group(P0.05),with no significant differences between the first two groups(P0.05).Area under the curve for both glucose and insulin 120 minutes after glucose load were lower in the sitagliptin and the metformin group compared with the db/db control group(P0.05),with no significant differences between the first two groups(P0.05).The liptin group showed a higher MNCV than both db/db and metformin groups(P0.05),whereas no significant difference were found between the db/db control and the metformin groups(P0.05).Conclusion Sitagliptin might be able to improve MNCV effectively in db/db mice,which was independent of the concurrent glucose lowering effect.
出处 《中国全科医学》 CAS CSCD 北大核心 2011年第18期2055-2058,共4页 Chinese General Practice
基金 国家自然科学基金资助项目(81000352) 中国博士后基金资助项目(20100471843) 江苏省博士后资助项目(1001027C)
关键词 糖尿病 2型 西格列汀 二甲双胍 坐骨神经 运动神经传导速度 Diabetes mellitus type 2 Sitagliptin Metformin Sciatic nerve Motor nerve conduction velocity
  • 相关文献

参考文献10

  • 1刘晓云.舒血宁注射液联合甲钴胺治疗糖尿病周围神经病变临床观察[J].中国误诊学杂志,2010,10(6):1343-1344. 被引量:2
  • 2高润祥,牛国地,马祥铭.血栓通注射液治疗糖尿病周围神经病变疗效观察[J].中国误诊学杂志,2009,9(28):6855-6856. 被引量:5
  • 3Perry T,Holloway HW,Weerasuriya A,et al.Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy[J].Exp Neurol,2007,203:293-230.
  • 4Ahren B.DPP-4 inhibitors[J].Best Pract Res Clin Endocrinol Metab,2007,21:517-533.
  • 5刘业强,朱育刚,史丽萍,于艳辉.糖尿病周围神经病变患者血管内皮生长因子与可溶性血管内皮生长因子受体-2的研究[J].疑难病杂志,2009,8(4):228-229. 被引量:7
  • 6Nakagawa A,Satake H,Nakabayashi H,et al.Receptor gene expression of glucagon-like peptide-1,but not glucose-dependent insulinotropic polypeptide,in rat nodose ganglion cells[J].Auton Neurosci,2004,110:36-43.
  • 7Biswas SC,Buteau J,Greene LA.Glucagon-like peptide-1(GLP-1)diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction[J].Neurochem Res,2008,33:1845-1851.
  • 8Oeseburg H,de Boer RA,Buikema H.Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A[J].Arterioscler Thromb Vasc Biol,2009,30:1407-1414.
  • 9Erdogdu O,Nathanson D,Sjoholm A.Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-,PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J].Mol Cell Endocrino,2010,325:26-35.
  • 10Jin HY,Liu WJ,Park JH,et al.Effect of dipeptidyl peptidase-Ⅳ(DPP-Ⅳ) inhibitor(Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats[J].Arch Med Res,2009,40:536-544.

二级参考文献14

  • 1辛沈,林朝胜,高柏青,贺顺川,边瓯,张平,焦明,刘丹阳,范娟,黄晓晶,郭艳.血栓通注射液治疗老年冠心病110例临床疗效观察[J].中国实用医药,2007,2(8):59-60. 被引量:9
  • 2辛颖.大剂量甲钴胺治疗糖尿病周围神经病变67例[J].中国药师,2006,9(1):53-53. 被引量:24
  • 3张福华,聂志奎.弥可保治疗糖尿病周围神经病变临床观察[J].现代中西医结合杂志,2006,15(7):897-897. 被引量:20
  • 4Cameron NE, Cotter MA. Vascular changes in animal models of diabetic neuropathy [ J ]. J Neurochem, 2003,85 ( Suppl 2 ) : 14.
  • 5Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a eDNA encoding secreted form of the extraeellular domain of the fit-1 vascular endothelial growth factor receptor[J]. Hum Gene Ther, 1998,9: 823-833.
  • 6Hanft JR, Pollak RA, Barbul A, et al. Phase I trial on the safety of topical rh- VEGF on chronic neuropathic diabetic foot ulcers[J]. J Wound Care,2008,17 (1) :30-37.
  • 7齐今吾.糖尿病的分型、分类及诊断与鉴别诊断//刘新民.实用内分泌学[M].3版.北京:人民军医出版社,2004:1219-1266.
  • 8赵明德,蔡德鸿,陈宏.糖尿病神经系统并发症//刘新民.实用内分泌学[M].3版.北京:人民军医出版社,2004:1414-1423.
  • 9Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer[J].J Clin Invest, 2001,107:1 083-1 092.
  • 10Storkebaum E, Lambrechts D, Canneliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection [ J ]. Bioessays, 2004, 26 (9) :943-954.

共引文献11

同被引文献76

  • 1刘军祥,叶运莉,李爱玲.糖尿病病人药物治疗依从性影响因素调查[J].现代预防医学,2007,34(14):2670-2671. 被引量:28
  • 2周佳.糖尿病患者遵医行为的调查研究[J].中华护理杂志,2009,24(11):1111-1113.
  • 3Liu W J,Xie S H,Liu Y N,et al. Dipeptidyl peptidase IV inhibitor at- tenuates kidney injury in streptozotocin - induced diabetic rats [ J ]. The Journal of pharmacology and experimental therapeutics, 2012,340 ( 2 ) : 248 - 255.
  • 4Edlin M.Compliance focus,education aid in diabetes management[J].Manag Healthcare Execut,2006,16(11):41.
  • 5Pan CY,Yang WY,Jia WP,et al.management of Chinese patients w ith type 2 diabetes,1998-2006:the Diabcare-China survey[J].Curr M ed Res&Opin,2009,25(1):39-45.
  • 6Turner RC,Cull CA,Frighi V,et al.Glycemic control with diet,sulfonylurea,metformin,or insulin in patients w ith type 2diabetes mellitus:progressive requirement for multiple therapies(UKPDS 49).UK Prospective Diabetes Study(UKPDS)Group[J].JAM A,1999,281(21):2005-2012.
  • 7China Diabetes society.Type 2 Diabetes Treatment Guideline.Beijing.
  • 8Chatterjee JS.From compliance to concordance in diabetes[J].J Med Ethics,2006,32:507-510.
  • 9International Diabetes Federation.The Diabetes Atlas.Fourth Edition.Brussels:International[C].Diabetes Federation,2009.
  • 10Yang WY,Lu JM,Wen JP,et al.Prevalence of diabetes among men and w omen in China[J].N Engl J M ed,2010,362:1090-1101.

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部